3/1/2012 9:24:04 AM
CAMBRIDGE, Mass. & WORCESTER, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, and the University of Massachusetts Medical School (UMMS) reported today that the European Patent Office (EPO) has upheld the Tuschl I ’726 patent (EP 1309726) in oral opposition proceedings held in Munich, Germany. The requested claims of the ’726 patent were upheld without any modification. Opponents included Sanofi-Aventis Deutschland GmbH, Silence Therapeutics AG, and BASF SE.
comments powered by